In a Phase 3 trial of more than 18,000 volunteers across three countries, an mRNA influenza vaccine from Pfizer has outperformed standard seasonal flu shots by 34.5%. It's yet another sign that this ...

Pfizer’s mRNA flu vaccine outperformed the standard flu shot in a Phase 3 clinical trial, according to results published Wednesday in the New England Journal of Medicine. The vaccine uses the same ...

Researchers at MIT have just developed a new lipid nanoparticle that super-enhances the effectiveness of the mRNA vaccine in mice to a hundred times its stand-alone effectiveness, thus offering ...

Vaccines that resemble viruses generally produce a stronger immune response, while mRNA versions are much quicker and cheaper to make. Now we are getting the best of both worlds, in the form of mRNA ...

EDITOR’S NOTE: The views expressed in this commentary are solely those of the writer. CNN is showcasing the work of The Conversation, a collaboration between journalists and academics to provide news ...

Deborah Fuller receives funding from the National Institutes of Health. She is co-founder and a scientific advisor for two biotech companies developing nucleic acid vaccine technologies that are not ...

The United States may be losing its edge in mRNA technology­­. The technology, which powered life-saving COVID-19 vaccines and is now rocketing new cancer therapeutics forward, will soon undergo a ...

Rick Bright, the former director of the Biomedical Advanced Research and Development Authority (BARDA) has warned that Department of Health and Human Services' decision to cut funding for mRNA vaccine ...

National Institutes of Health (NIH) Director Jay Bhattacharya claims the federal government recently canceled millions of dollars’ worth of mRNA research contracts because the general public does not ...

Sara Moniuszko is a health and lifestyle reporter at CBSNews.com. Previously, she wrote for USA Today, where she was selected to help launch the newspaper's wellness vertical. She now covers breaking ...

Settlement reached over mRNA-based COVID vaccines CureVac and GSK get $740 million upfront, and royalties BioNTech's deal to buy CureVac on track GSK's own lawsuits against Pfizer, BioNTech unaffected ...